Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (NCT04071223)
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (47 Sites)
Showing the first 25 of 47 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- UC San Diego Moores Cancer Center — La Jolla, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Rush MD Anderson Cancer Center — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
- Loyola University Medical Center — Maywood, Illinois
- UC Comprehensive Cancer Center at Silver Cross — New Lenox, Illinois
- Rush MD Anderson Cancer Center at Rush Oak Park — Oak Park, Illinois
- University of Chicago Medicine-Orland Park — Orland Park, Illinois
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Iowa Methodist Medical Center — Des Moines, Iowa
- UI Health Care Mission Cancer and Blood - Des Moines Clinic — Des Moines, Iowa
- University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
- University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
- East Jefferson General Hospital — Metairie, Louisiana
- LSU Healthcare Network / Metairie Multi-Specialty Clinic — Metairie, Louisiana
- Tulane University School of Medicine — New Orleans, Louisiana
- Dana-Farber Cancer Institute — Boston, Massachusetts
- UMass Memorial Medical Center - University Campus — Worcester, Massachusetts
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Henry Ford Hospital — Detroit, Michigan
- Trinity Health Saint Mary Mercy Livonia Hospital — Livonia, Michigan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Renal Cell Carcinoma
- A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma — Washington D.C., District of Columbia
- Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC — La Jolla, California
- Sitagliptin With Pembro in RCC and Melanoma — Iowa City, Iowa
Explore by condition: All Advanced Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.